Goods & Services

Software for the recording, viewing, or analyzing health and medical information; software applications for mobile devices for the recording, viewing, or analyzing health and medical information; web application software for the recording, viewing, or analyzing health and medical information. Scientific and technological services, namely, scientific research, analysis, testing, of medical devices and medicines in the field of pharmaceuticals and human healthcare; software as a service [SaaS]. Providing medical information, consultancy and advisory services relating to eye diseases, eye infections and eye symptoms; medical services relating to eye diseases, eye infections and eye symptoms; human healthcare services relating to eye diseases, eye infections and eye symptoms; medical and pharmaceutical counseling relating to eye diseases, eye infections and eye symptoms; treatment of eye diseases, eye infections and eye symptoms; offering medical information on diseases and on the treatment thereof.

Goods & Services

Ophthalmologic preparations; eye drops; pharmaceutical preparations; veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use; food for babies; plasters; materials for dressings; material for stopping teeth; dental wax; disinfectants; fungicides; herbicides.

Goods & Services

Eye drops for the reduction of myopia progression; collyrium; eye drops; ophthalmic pharmaceutical preparations; ophthalmological preparations; pharmaceutical preparations for the treatment of cataracts; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of ocular hypertension; ophthalmic ointments, creams, lotions and gels; pharmaceutical preparations for use in eye injections; pharmaceutical preparations for the treatment of pinguecula; pharmaceutical preparations for the treatment of chalazion; pharmaceutical preparations for the treatment of uveitis; pharmaceutical preparations for improving focus-adjustment function declined by accommodative asthenopia; pharmaceutical preparations for the treatment of accommodative asthenopia; eye drops for the treatment of keratoconjunctival epithelial disorder; antibacterial eye drops; antiallergic eye drops; pharmaceutical preparations; dietary supplements for humans; nutritional supplements.

Abstract

Disclosed herein is an aqueous composition comprising 0.001-0.1% (w/v) atropine or a salt thereof, a water-soluble polymer, and buffer (1), which is at a pH range of 6 or lower, wherein the buffer (1) is at least one selected from the group consisting of a phosphate buffer, an aminocarboxylate buffer, a carbonate buffer, an acetate buffer, a tartrate buffer, a borate buffer, and trometamol.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
• A61K 47/02 - Inorganic compounds
• A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 27/02 - Ophthalmic agents
• A61P 27/08 - Mydriatics or cycloplegics
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.

IPC Classes  ?

• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/225 - Polycarboxylic acids
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The present invention provides an aqueous composition that improves transferability to eye tissue and a preservative effect, that comprises epinastine or a salt thereof in a concentration of 0.1% (w/v), boric acid and/or a salt thereof, and an isotonizing agent, and that has a pH of 6.0-7.7, wherein the concentration of the boric acid and/or the salt thereof is 150-500 mM in terms of boron concentration.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 9/08 - Solutions
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61P 27/14 - Decongestants or antiallergics

Goods & Services

Intraocular prostheses [lenses] for surgical implantation; intraocular lens injector; eye droppers for medical purposes; glaucoma tube shunt; surgical apparatus and instruments for use in ophthalmic surgery; medical devices for non-laser glaucoma surgery; ocular implants and devices; shunts for use in treating glaucoma; stents for use in treating glaucoma; ophthalmic cutting instruments for use in treating glaucoma; shunt and stent applicators for use in treating glaucoma; vision screening instruments for use in treating glaucoma; ocular implants and devices for use in treating glaucoma; ophthalmic medical devices; syringes for medical purposes; medical apparatus; eye wash cups for medical purposes; finger guards for medical purposes; pacifier clips; ice bag pillows for medical purposes; triangular bandages; supportive bandages; surgical catguts; feeding cups for medical purposes; dropping pipettes for medical purposes; medical ice bags; medical ice bag holders; nursing bottles; contraceptive devices; artificial tympanic membranes; prosthetic or filling materials, not for dental use; esthetic massage apparatus for commercial use; electric massage apparatus for household use; gloves for medical purposes.

Abstract

The present disclosure provides a pharmaceutical composition comprising ursodeoxycholic acid or a salt thereof, a preservative, and water.

IPC Classes  ?

• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

The present invention provides a pharmaceutical composition for application to the skin comprising epinastine or a salt thereof in a concentration of 0.05 to 1% (w/w) as an active ingredient which can maintain the concentration of the active ingredient for a long time even at lower concentrations.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61P 27/14 - Decongestants or antiallergics

Abstract

The present invention provides a pharmaceutical composition for transdermal administration comprising epinastine or a salt thereof as an active ingredient which can maintain the effective concentration of epinastine or a salt thereof in an ocular tissue and stabilize epinastine or a salt thereof in the pharmaceutical composition for a long time.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Goods & Services

Ophthalmic preparations.

Abstract

The present disclosure provides a pharmaceutical composition containing ursodeoxycholic acid or a salt thereof, trometamol or a salt thereof, and water, the pharmaceutical composition having an osmotic pressure of 50-400 mOsm/L, and the amount of trometamol or a salt thereof contained in the pharmaceutical composition being 0.01-3%(w/v).

IPC Classes  ?

• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 9/08 - Solutions
• A61K 47/02 - Inorganic compounds
• A61K 47/04 - Non-metalsCompounds thereof
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61P 27/02 - Ophthalmic agents
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

The purpose of the present invention is to provide a pharmaceutical composition that comprises a specific compound and exhibits a superior preservation efficacy, the specific compound being stable within the pharmaceutical composition, and to provide methods for improving the stability of the specific compound within the pharmaceutical composition and the preservation efficacy of the pharmaceutical composition. The pharmaceutical composition according to the present invention comprises isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and further comprises edetic acid or a salt thereof.

IPC Classes  ?

• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.

IPC Classes  ?

• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61P 27/06 - Antiglaucoma agents or miotics
• A61P 27/02 - Ophthalmic agents
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention provides a stable pharmaceutical composition comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof and a method of stabilizing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof

Abstract

The purpose of the present invention is to provide: a pharmaceutical composition that comprises the pyridylaminoacetic acid compound of the present invention, said pyridylaminoacetic acid compound being stable within the pharmaceutical composition; and a method for improving the stability of the pydridylaminoacetic acid compound within the pharmaceutical composition. The pharmaceutical composition comprises: (6{[4-(pyrazol-1-yl)benzyl](pyridine-3-ylsulfonyl)aminomethyl}pyridine-2-ylamino)isopropyl acetate or a salt thereof; and polyoxyethylene castor oil. The polyoxyethylene castor oil preferably comprises a polyoxyethylene castor oil selected from the group consisting of polyoxyl 5 castor oil, polyoxyl 9 castor oil, polyoxyl 15 castor oil, polyoxyl 35 castor oil, and polyoxyl 40 castor oil.

IPC Classes  ?

• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/02 - Inorganic compounds
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions

Abstract

A method of delivering a dose from a single dose syringe includes applying a user input to a rotational component of a plunger rod assembly that is engaged with a plunger rod of the plunger rod assembly to advance a plunger seal in a direction parallel to an axis of rotation of the rotational component from an initial position towards a start of dose delivery position, and upon disengagement of the rotational component from the plunger rod, applying an axial user input to the plunger rod of the plunger rod assembly to advance the plunger seal from the start of dose delivery position to a completion of dose delivery position to deliver the dose, wherein the completion of dose delivery position is defined by abutment between the plunger rod and a housing of the plunger rod assembly.

IPC Classes  ?

• A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 5/31 - Syringes Details
• A61M 5/34 - Constructions for connecting the needle
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61M 39/10 - Tube connectors or tube couplings

Abstract

The present disclosure provides an agent for treating or preventing an eye disease such as presbyopia, comprising, as an active ingredient, a sulfur-containing compound having a specified structure.

IPC Classes  ?

• A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
• A61K 31/095 - Sulfur, selenium or tellurium compounds, e.g. thiols
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

The purpose of the present invention is to discover a method for stabilizing a composition for ophthalmic use containing sepetaprost, more specifically, a method that facilitates retention of sepetaprost stability at high temperatures, and further, a method that facilitates the retention of shelf life of this composition for ophthalmic use.　The present invention is a composition for ophthalmic use, which contains sepetaprost at a concentration of 0.0001 to 0.003% (w/v) and has a pH within a range from 5 to 8.

IPC Classes  ?

• A61K 31/558 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
• A61K 9/08 - Solutions
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 27/02 - Ophthalmic agents
• A61P 27/06 - Antiglaucoma agents or miotics

Abstract

The present invention provides a pharmaceutical preparation in which an aqueous pharmaceutical composition, which contains (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof, is housed in a packaging that blocks light rays of 210-380 nm in wavelength. In this pharmaceutical preparation, the stability of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in the aqueous pharmaceutical composition has been improved.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 9/08 - Solutions
• A61P 27/06 - Antiglaucoma agents or miotics

Abstract

The present invention provides an effective production method and/or purification method for a high-yield and high-purity (R)-11-[[-[(diethylamino)methyl]-1-piperidinyl]-acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-one or a salt thereof, said compound not containing impurities, particularly 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-one.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61P 27/02 - Ophthalmic agents
• A61P 27/06 - Antiglaucoma agents or miotics

Abstract

The purpose of the present invention is to identify a drug formulation for the treatment or prevention of glaucoma or ocular hypertension, wherein the drug formulation exhibits an effect in patients with drug-refractory glaucoma or ocular hypertension. Sepetaprost is expected to exhibit an excellent intraocular pressure-lowering action in patients with otherwise drug-refractory glaucoma or ocular hypertension. The drug formulation according to the present invention containing sepetaprost as an active ingredient is therefore useful as a drug formulation that can treat or prevent glaucoma or ocular hypertension in patients with otherwise drug-refractory glaucoma or ocular hypertension.

IPC Classes  ?

• A61K 31/558 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
• A61P 27/06 - Antiglaucoma agents or miotics
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention provides an improvement in the strength of the scleral by collagen fiber crosslinking via crosslinking treatment of the sclera at the equatorial region of the eye and/or at the posterior pole such as the fundus of the eye. Also provided is the prevention and/or treatment of eye disease by the same. Provided are a photosensitizer used in a crosslinking treatment for the sclera at the equatorial region of the eye and/or at the posterior pole of the eye; a kit containing the same; and a method for emitting light for the crosslinking treatment.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide

Abstract

The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.

IPC Classes  ?

• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha

Goods & Services

Software for the recording, viewing, or analyzing health and medical information; software applications for mobile devices for the recording, viewing, or analyzing health and medical information. Scientific and technological services, namely, scientific research, analysis, testing, of medical devices and medicines in the field of pharmaceuticals and human healthcare; offering information on diseases and on the treatment thereof. Providing medical information, consultancy and advisory services relating to eye diseases, eye infections and eye symptoms; Medical services relating to eye diseases, eye infections and eye symptoms; human healthcare services relating to eye diseases, eye infections and eye symptoms; medical and pharmaceutical counseling relating to eye diseases, eye infections and eye symptoms.

Abstract

A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Abstract

The present invention relates to a pharmaceutical composition for treating myopia, preventing myopia and/or suppressing myopia progression, comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient, wherein the pharmaceutical composition is substantially free of (−)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 27/06 - Antiglaucoma agents or miotics

Goods & Services

Collyrium; eye drops; ophthalmic pharmaceutical preparations; ophthalmological preparations; pharmaceutical preparations for treatment of cataracts; pharmaceutical preparations for treatment of glaucoma; pharmaceutical preparations for treatment of ocular hypertension; ophthalmic ointments, creams, lotions and gels; pharmaceutical preparations for use in eye injections; pharmaceutical preparations for treatment of pinguecula; pharmaceutical preparations for treatment of chalazion; pharmaceutical preparations for treatment of uveitis; pharmaceutical preparations for improving focus-adjustment function declined by accommodative asthenopia; pharmaceutical preparations for treatment of accommodative asthenopia; eye drops for treatment of keratoconjunctival epithelial disorder; antibacterial eye drops; antiallergic eye drops; pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for medical use; capsules for medicines; eyepatches for medical purposes; ear bandages for medical purposes; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton sticks for medical purposes; diapers; diaper covers; dietary supplements for humans; nutritional supplements; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals.

Goods & Services

Collyrium; eye drops; ophthalmic pharmaceutical preparations; ophthalmological preparations; pharmaceutical preparations for treatment of cataracts; pharmaceutical preparations for treatment of glaucoma; pharmaceutical preparations for treatment of ocular hypertension; ophthalmic ointments, creams, lotions and gels; pharmaceutical preparations for use in eye injections; pharmaceutical preparations for treatment of pinguecula; pharmaceutical preparations for treatment of chalazion; pharmaceutical preparations for treatment of uveitis; pharmaceutical preparations for improving focus-adjustment function declined by accommodative asthenopia; pharmaceutical preparations for treatment of accommodative asthenopia; eye drops for treatment of keratoconjunctival epithelial disorder; antibacterial eye drops; antiallergic eye drops; pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for medical use; capsules for medicines; eyepatches for medical purposes; ear bandages for medical purposes; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton sticks for medical purposes; diapers; diaper covers; dietary supplements for humans; nutritional supplements; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals.

Abstract

The present invention relates to an ophthalmic aqueous composition containing a silver salt, and filled in a container made of a polyester-based resin, or a container made of a polyolefin-based resin excluding polypropylene. Besides, the present invention also relates to an ophthalmic preservative containing a silver salt, and filled in a container made of a polyester-based resin or a container made of a polyolefin-based resin excluding polypropylene, and a method for imparting, to an ophthalmic aqueous composition, preservative efficacy satisfying a criterion of Preservatives-Effectiveness Tests of The Japanese Pharmacopoeia, including adding a silver salt to the ophthalmic aqueous composition, and filling the ophthalmic aqueous composition in a container made of a polyester-based resin or a container made of a polyolefin-based resin excluding polypropylene. The present invention provides a preservative/system widely usable in ophthalmic aqueous compositions regardless of types of active ingredients and additives.

IPC Classes  ?

• A61K 47/02 - Inorganic compounds
• A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
• A61K 9/08 - Solutions
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin

Abstract

The present disclosure provides: a sulfur-containing compound which has a predetermined structure and is useful for treating or preventing eye diseases such as presbyopia and cataracts; and an agent for treating or preventing eye diseases such as presbyopia and cataracts, the agent containing said sulfur-containing compound as an active ingredient.

IPC Classes  ?

• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 27/02 - Ophthalmic agents
• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. The present invention relates to a medicament for preventing and/or treating dry eye, comprising olodaterol or a salt thereof as an active ingredient.

IPC Classes  ?

• A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• A61P 27/02 - Ophthalmic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. The present invention relates to a medicament for preventing and/or treating dry eye, comprising olodaterol or a salt thereof as an active ingredient.

IPC Classes  ?

• A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• A61P 27/02 - Ophthalmic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The purpose of the present invention is to provide an aqueous suspension composition comprising poorly water-soluble sirolimus or a salt thereof for ophthalmology, in particular, used for topical administration, such as a less invasive eye drop. The purpose of the present invention is to provide an aqueous suspension composition comprising poorly water-soluble sirolimus or a salt thereof for ophthalmology, in particular, used for topical administration, such as a less invasive eye drop. The present invention is an ophthalmic aqueous suspension composition comprising sirolimus or a salt thereof and a surfactant, wherein the aqueous suspension composition has a pH of 4 to 6.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 9/10 - DispersionsEmulsions
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids

Abstract

The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to the use of valproic acid for reducing post-operative scarring following a glaucoma surgery. In one embodiment, the glaucoma surgery is glaucoma filtering surgery, which comprises creating a subconjunctival bleb. In another embodiment, the glaucoma surgery is minimally invasive glaucoma surgery (MIGS), which comprises implanting a glaucoma tube shunt under a subconjunctival space.

IPC Classes  ?

• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
• A61P 27/02 - Ophthalmic agents
• A61P 41/00 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Goods & Services

Educational services..

Abstract

Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 27/06 - Antiglaucoma agents or miotics

Abstract

An examination system (1000) comprises: a camera (16); a processor (21) for examining the wetness of an eye, on the basis of captured images obtained as a result of the camera (16) imaging the eye, and an estimation model (232) that includes a neural network (2321); and a display (15) that displays the results of the examination executed by the processor (21).

IPC Classes  ?

• G06T 7/00 - Image analysis
• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions

Goods & Services

Educational services. Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; hosting of websites. Medical services; providing medical information; medical counselling services; provision of pharmaceutical information.

Abstract

The present disclosure provides a pharmaceutical composition comprising ursodeoxycholic acid or a salt thereof, a preservative agent and water.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 47/04 - Non-metalsCompounds thereof
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 27/02 - Ophthalmic agents
• A61P 27/04 - Artificial tearsIrrigation solutions

Abstract

The present disclosure provides a pharmaceutical composition comprising ursodeoxycholic acid or a salt thereof, a preservative agent and water.

IPC Classes  ?

• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 9/08 - Solutions
• A61K 47/04 - Non-metalsCompounds thereof
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 27/02 - Ophthalmic agents
• A61P 27/04 - Artificial tearsIrrigation solutions

Goods & Services

Educational services. Scientific and technological services; offering scientific information on diseases and on the treatment thereof; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; hosting of websites. Medical services; healthcare services; providing of medical information; medical counselling services; provision of pharmaceutical information.

Goods & Services

(1) Educational services in the field of eye care and eye treatment products (2) Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; hosting websites. (3) Medical services, namely, medical analysis for ophthalmological and eye disease prevention, screening, diagnosis and treatment; Providing medical information in the field of eye care and eye treatment; Medical counselling in the field of eye care and eye treatment; provision of pharmaceutical information.

Abstract

The present invention provides a method for producing a layered retinal tissue including photoreceptor cells from pluripotent stem cells or an aggregate including retinal progenitor cells within a short period.

IPC Classes  ?

• C12N 5/079 - Neural cells
• C12Q 1/06 - Quantitative determination

Abstract

The present invention provides a pharmaceutical composition for topical administration, which contains epinastine or a salt thereof as an active ingredient at a concentration of 0.05 to 1% (w/w) and which enables long-term retention of the active ingredient concentration in eye tissue even when the dose is a low concentration.

IPC Classes  ?

• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 9/06 - OintmentsBases therefor
• A61K 9/107 - Emulsions
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 27/02 - Ophthalmic agents
• A61P 27/14 - Decongestants or antiallergics
• A61P 37/08 - Antiallergic agents

Abstract

The present invention provides a pharmaceutical composition for transdermal administration, the pharmaceutical composition being capable of maintaining an effective concentration in eye tissue and maintaining stability for a long time, and containing epinastine or a salt thereof and a sulfur-based antioxidant.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 9/06 - OintmentsBases therefor
• A61K 9/10 - DispersionsEmulsions
• A61K 9/107 - Emulsions
• A61K 47/02 - Inorganic compounds
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 27/02 - Ophthalmic agents
• A61P 27/14 - Decongestants or antiallergics
• A61P 39/06 - Free radical scavengers or antioxidants

Goods & Services

Collyrium; eye drops; ophthalmic pharmaceutical preparations; ophthalmological preparations; pharmaceutical preparations for treatment of cataracts; pharmaceutical preparations for treatment of glaucoma; pharmaceutical preparations for treatment of ocular hypertension; ophthalmic ointments, creams, lotions and gels; pharmaceutical preparations for use in eye injections; pharmaceutical preparations for treatment of pinguecula; pharmaceutical preparations for treatment of chalazion; pharmaceutical preparations for treatment of uveitis; pharmaceutical preparations for improving focus-adjustment function declined by accommodative asthenopia; pharmaceutical preparations for treatment of accommodative asthenopia; eye drops for treatment of keratoconjunctival epithelial disorder; antibacterial eye drops; antiallergic eye drops; pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for medical use; capsules for medicines; eyepatches for medical purposes; ear bandages for medical purposes; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton sticks for medical purposes; diapers; diaper covers; dietary supplements for humans; nutritional supplements; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals.

Goods & Services

(1) Pharmaceutical preparations for ophthalmological use; Sanitary preparations for medical purposes for the treatment of eye diseases and eye conditions.

Goods & Services

Collyrium; eye drops; ophthalmic pharmaceutical preparations; ophthalmological preparations; pharmaceutical preparations for treatment of cataracts; pharmaceutical preparations for treatment of glaucoma; pharmaceutical preparations for treatment of ocular hypertension; ophthalmic ointments, creams, lotions and gels; pharmaceutical preparations for use in eye injections; pharmaceutical preparations for treatment of pinguecula; pharmaceutical preparations for treatment of chalazion; pharmaceutical preparations for treatment of uveitis; pharmaceutical preparations for improving focus-adjustment function declined by accommodative asthenopia; pharmaceutical preparations for treatment of accommodative asthenopia; eye drops for treatment of keratoconjunctival epithelial disorder; antibacterial eye drops; antiallergic eye drops; pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for medical use; capsules for medicines; eyepatches for medical purposes; ear bandages for medical purposes; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton sticks for medical purposes; diapers; diaper covers; dietary supplements for humans; nutritional supplements; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals.

Goods & Services

Breath freshening preparations; soaps and detergents; dentifrices; cosmetics; make-up powder; toilet water; beauty serums; eye cream for cosmetic purposes; beauty balm creams; gel eye patches for cosmetic purposes; gel eye masks; cosmetic creams; cosmetic oils; eye lotions for cosmetic purposes; cosmetic rouges; hair care preparations; perfumes; natural perfumery prepared from vegetables; natural perfumery prepared from animals; synthetic perfumery; blended perfumery; incense; false eyelashes. Collyrium; eye drops; medicinal creams; medicated lotions; balms for medical purposes; ointments for pharmaceutical purposes; ophthalmic preparations; pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; tapes (adhesive -), for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary pads; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals; semen for artificial insemination. Intraocular lenses; intraocular lens injector; eye droppers for medical purposes; glaucoma tube shunt; ophthalmologic apparatus and instruments; syringes for medical purposes; medical apparatus and instruments; cups for eye-washes; finger guards for medical purposes; pacifier clips; ice bag pillows for medical purposes; triangular bandages; supportive bandages; surgical catguts; feeding cups for medical purposes; dropping pipettes for medical purposes; teats; ice bags for medical purposes; medical ice bag holders; baby bottles; nursing bottles; contraceptive devices; artificial tympanic membranes; prosthetics or fillings materials, not for dental use; ear plugs for sleeping; ear plugs for protection against noise; esthetic massage apparatus for commercial use; electric massage apparatus for household purposes; gloves for medical purposes; portable hand-held urinals; bed pans; ear picks; sanitary masks for medical purposes; parts, fittings and accessories for all the aforementioned goods. Advertising and publicity services; promoting the goods and services of others through the administration of sales and promotional incentive schemes involving trading stamps; business management analysis or business consultancy; marketing research or analysis; providing information concerning commercial sales; business management; business administration services for the processing of sales made on the internet; promoting the goods and services of others over the internet; provision of an online marketplace for buyers and sellers of goods and services; commercial intermediation services; commercial administration of the licensing of the goods and services of others; administration of consumer loyalty programs; website traffic optimization; presentation of goods on communication media, for retail purposes; auctioneering; import-export agency services; publicity material rental; rental of advertising space; providing commercial information and advice for consumers in the choice of products and services; retail services or wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; retail services or wholesale services for cosmetics, toiletries, dentifrices, soaps and detergents. Educational and instruction services relating to arts, crafts, sports or general knowledge; teaching; educational and instruction services; teaching in the field of cosmetics and medicines; arranging, conducting and organization of seminars; arranging and conducting of seminars, workshops [education], congresses, colloquia, distance learning courses and exhibitions for cultural purposes; providing electronic publications; providing videos from the internet, not downloadable; providing digital music from the internet, not downloadable; providing images from the internet, not downloadable; entertainment services; entertainment information; photography. Providing information about beauty; beauty consultancy; provision of medical information; providing information relating to ophthalmology services; dietary and nutritional guidance; providing information relating to dietary and nutritional guidance; providing information relating to nursing care; nursing home services; medical equipment rental; providing information relating to the rental of medical machines and apparatus; health care.

Goods & Services

Breath freshening preparations; soaps and detergents; dentifrices; cosmetics; make-up powder; toilet water; beauty serums; eye cream for cosmetic purposes; beauty balm creams; gel eye patches for cosmetic purposes; gel eye masks; cosmetic creams; cosmetic oils; eye lotions for cosmetic purposes; cosmetic rouges; hair care preparations; perfumes; materials; natural perfumery prepared from vegetables; natural perfumery prepared from animals; synthetic perfumery; blended perfumery; incense; false eyelashes. Collyrium; eye drops; medicinal creams; medicated lotions; balms for medical purposes; ointments for pharmaceutical purposes; ophthalmic preparations; pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; tapes (adhesive -), for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary pads; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals; semen for artificial insemination. Laboratory apparatus and instruments; measuring or testing machines and instruments; sensors [measurement apparatus], other than for medical use; telecommunication machines and apparatus; personal digital assistants; application software for mobile devices; electronic machines, apparatus and their parts; computer programs; computers and their peripherals; computer software applications, downloadable; computer software, recorded; eyeglasses; downloadable music files; downloadable image files; downloadable video files; electronic publications; parts, fittings and accessories for all the aforementioned goods. Intraocular lenses; intraocular lens injector; eye droppers for medical purposes; glaucoma tube shunt; ophthalmologic apparatus and instruments; syringes for medical purposes; medical apparatus and instruments; cups for eye-washes; finger guards for medical purposes; pacifier clips; ice bag pillows for medical purposes; triangular bandages; supportive bandages; surgical catguts; feeding cups for medical purposes; dropping pipettes for medical purposes; teats; ice bags for medical purposes; medical ice bag holders; baby bottles; nursing bottles; contraceptive devices; artificial tympanic membranes; prosthetics or fillings materials, not for dental use; ear plugs for sleeping; ear plugs for protection against noise; esthetic massage apparatus for commercial use; electric massage apparatus for household purposes; gloves for medical purposes; portable hand-held urinals; bed pans; ear picks; sanitary masks for medical purposes; parts, fittings and accessories for all the aforementioned goods. Advertising and publicity services; promoting the goods and services of others through the administration of sales and promotional incentive schemes involving trading stamps; business management analysis or business consultancy; marketing research or analysis; providing information concerning commercial sales; business management; business administration services for the processing of sales made on the internet; promoting the goods and services of others over the internet; provision of an online marketplace for buyers and sellers of goods and services; commercial intermediation services; commercial administration of the licensing of the goods and services of others; administration of consumer loyalty programs; website traffic optimization; presentation of goods on communication media, for retail purposes; auctioneering; import-export agency services; publicity material rental; rental of advertising space; providing commercial information and advice for consumers in the choice of products and services; retail services or wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; retail services or wholesale services for cosmetics, toiletries, dentifrices, soaps and detergents. Educational and instruction services relating to arts, crafts, sports or general knowledge; teaching; educational and instruction services; teaching in the field of cosmetics and medicines; arranging, conducting and organization of seminars; arranging and conducting of seminars, workshops [education], congresses, colloquia, distance learning courses and exhibitions for cultural purposes; providing electronic publications; providing videos from the internet, not downloadable; providing digital music from the internet, not downloadable; providing images from the internet, not downloadable; entertainment services; entertainment information; photography. Designing of machines, apparatus, instruments [including their parts] or systems composed of such machines, apparatus and instruments; design services; computer programming; creation, design and maintenance of web sites; creation, maintenance, and updating of computer software; monitoring of computer systems by remote access; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs; quality control; rental of computers; providing computer programs on data networks; rental of web servers; cloud computing; software as a service [SaaS]; platform as a service [PaaS]; hosting computer sites [web sites]; electronic data storage. Providing information about beauty; beauty consultancy; provision of medical information; providing information relating to ophthalmology services; dietary and nutritional guidance; providing information relating to dietary and nutritional guidance; providing information relating to nursing care; nursing home services; medical equipment rental; providing information relating to the rental of medical machines and apparatus; health care.

Abstract

The problem addressed by the present invention is that of searching for an easy-to-handle diquafosol/preservative combination for preparing a diquafosol ophthalmic solution that does not exhibit a change in formulation, is clear in color, and also has sufficient preservative efficacy.　The present invention is an aqueous ophthalmic solution containing diquafosol or a salt thereof as an active ingredient, and containing an alkyldiaminoethylglycine or a salt thereof.

IPC Classes  ?

• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 9/08 - Solutions
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61P 27/02 - Ophthalmic agents
• A61P 27/04 - Artificial tearsIrrigation solutions

Abstract

The present invention addresses the problem of searching for an easily handleable combination of diquafosol and an antiseptic agent when producing a clear diquafosol eye drop having sufficient preservation efficacy.　The present invention is an aqueous eye drop which contains diquafosol or a salt thereof as an active ingredient and contains polidronium chloride.

IPC Classes  ?

• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 9/08 - Solutions
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 27/02 - Ophthalmic agents
• A61P 27/04 - Artificial tearsIrrigation solutions

Abstract

The present invention addresses the problem of exploring an additional combination of diquafosol and a preservative, said combination enabling the preparation of a clear diquafosol ophthalmic solution, while having sufficient preservative efficacy.　The present invention provides an aqueous ophthalmic solution which contains diquafosol or a salt thereof as an active ingredient, while also containing polyhexamethylene biguanide or a salt thereof.

IPC Classes  ?

• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 9/08 - Solutions
• A61K 47/16 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen
• A61P 27/02 - Ophthalmic agents
• A61P 27/04 - Artificial tearsIrrigation solutions

Abstract

The present disclosure provides and an agent for treating or preventing an eye disease such as presbyopia, comprising, as an active ingredient, a lipoic acid prodrug having a specified structure.

IPC Classes  ?

• A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia

Goods & Services

Collyrium; eye drops; ophthalmic pharmaceutical preparations; ophthalmological preparations; pharmaceutical preparations for treatment of cataracts; pharmaceutical preparations for treatment of glaucoma; pharmaceutical preparations for treatment of ocular hypertension; ophthalmic ointments, creams, lotions and gels; pharmaceutical preparations for use in eye injections; pharmaceutical preparations for treatment of pinguecula; pharmaceutical preparations for treatment of chalazion; pharmaceutical preparations for treatment of uveitis; pharmaceutical preparations for improving focus-adjustment function declined by accommodative asthenopia; pharmaceutical preparations for treatment of accommodative asthenopia; eye drops for treatment of keratoconjunctival epithelial disorder; antibacterial eye drops; antiallergic eye drops; pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for medical use; capsules for medicines; eyepatches for medical purposes; ear bandages for medical purposes; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton sticks for medical purposes; diapers; diaper covers; dietary supplements for humans; nutritional supplements; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals.

Abstract

To prove an optical probe that can illuminate an entire desired region at one time, even in a narrow space. An optical probe including: a linear light guide to guide light from a light source device; a planar emitter to be connected to a tip portion of the linear light guide, to emit the light; a reflective surface provided in a part of the planar emitter, to reflect the light having entered the planar emitter; and an emitting surface provided so as to face the reflective surface, to allow the light reflected by the reflective surface to be emitted from a region of the reflective surface.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light

Abstract

The present invention provides: a stable pharmaceutical composition containing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyrido[2, 3-b][1, 4]benzodiazepine-6-one or a salt thereof; and a method for stabilizing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyrido[2, 3-b][1, 4]benzodiazepine-6-one or a salt thereof.

IPC Classes  ?

• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention provides: a stable pharmaceutical composition containing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyrido[2, 3-b][1, 4]benzodiazepine-6-one or a salt thereof; and a method for stabilizing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyrido[2, 3-b][1, 4]benzodiazepine-6-one or a salt thereof.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61P 27/02 - Ophthalmic agents

Abstract

The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present disclosure relates to bispecific binding molecules against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), including protein sequences, methods for their production, pharmaceutical compositions containing the bispecific binding molecules, and therapeutic and diagnostic uses thereof.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 27/04 - Artificial tearsIrrigation solutions
• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/13 - Immunoglobulins
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C12P 21/08 - Monoclonal antibodies

Abstract

The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia
• A61K 9/00 - Medicinal preparations characterised by special physical form

Goods & Services

Educational services. Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; hosting websites. Medical services; providing medical information; medical counselling services; provision of pharmaceutical information.

Abstract

Provided is an ophthalmic composition comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. Also provided is an agent for prevention or treatment of dry eyes, comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. These solution-type aqueous eye drop for treatment of dry eye each comprises diquafosol sodium with a concentration of 3% (w/v), hydroxyethyl cellulose and polyvinylpyrrolidone having a K value of 30, and is characterized in that a single dose of 1 to 2 drops is administered by eye drop three times per day.

IPC Classes  ?

• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions

Abstract

Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.

IPC Classes  ?

• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61P 27/06 - Antiglaucoma agents or miotics
• A61P 27/02 - Ophthalmic agents
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The purpose of the present invention is to identify a drug formulation for the treatment or prevention of glaucoma or ocular hypertension, wherein the drug formulation exhibits an effect in patients with drug-refractory glaucoma or ocular hypertension.　Sepetaprost is expected to exhibit an excellent intraocular pressure-lowering action in patients with otherwise drug-refractory glaucoma or ocular hypertension. The drug formulation according to the present invention containing sepetaprost as an active ingredient is therefore useful as a drug formulation that can treat or prevent glaucoma or ocular hypertension in patients with otherwise drug-refractory glaucoma or ocular hypertension.

IPC Classes  ?

• A61K 31/558 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 27/06 - Antiglaucoma agents or miotics

Abstract

The present invention relates to a pharmaceutical composition for treating myopia, preventing myopia and/or suppressing myopia progression, comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient, wherein the pharmaceutical composition is substantially free of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

IPC Classes  ?

• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61P 27/02 - Ophthalmic agents
• A61P 27/06 - Antiglaucoma agents or miotics

Abstract

A drive unit 100 for liquid ejection allows a user to eject a fixed amount of liquid easily and economically without complicating manufacturing tasks and liquid replenishment tasks, and is for actuating a pump bottle 10 having a discharge port 13, a storage part 11, and a support base 12, the pump bottle being configured such that when the storage part 11 moves, relative to the support base 12, from a normal state position to an operation position, liquid stored in the storage part 11 is ejected through the discharge port 13. This drive unit for liquid ejection comprises: a unit body 20 that allows installation of the pump bottle 10 with the discharge port 13 exposed to the outside; a pusher 35 which is provided to the unit body 20 such that the pusher can face the pump bottle 10 installed to the unit body 20 and can move along the movement direction of the storage part 11; and a main drive member 31, a driven member 32, and a biasing spring 33 which are for moving, relative to the unit body 20, the pusher 35 between the normal state position and the operation position, such movement driven by an electric motor 40.

IPC Classes  ?

• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes

Abstract

The present invention relates to a pharmaceutical composition for treating myopia, preventing myopia and/or suppressing myopia progression, comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient, wherein the pharmaceutical composition is substantially free of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61P 27/02 - Ophthalmic agents
• A61P 27/06 - Antiglaucoma agents or miotics

Abstract

The present invention provides an improvement in the strength of the scleral by collagen fiber crosslinking via crosslinking treatment of the sclera at the equatorial region of the eye and/or at the posterior pole such as the fundus of the eye. Also provided is the prevention and/or treatment of eye disease by the same. Provided are: a photosensitizer used in a crosslinking treatment for the sclera at the equatorial region of the eye and/or at the posterior pole of the eye; a kit containing the same; and a method for emitting light for the crosslinking treatment.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61F 9/007 - Methods or devices for eye surgery
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 41/17 - Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

The present invention provides a novel VEGF-binding peptide or a compound including a novel VEGF-binding peptide structure. For example, the present invention provides a compound represented by the following formula (I) (where peptide A is represented by the following formula (A), and each of the groups is as defined in the description) or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07K 7/50 - Cyclic peptides containing at least one abnormal peptide link
• A61K 38/12 - Cyclic peptides
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 7/10 - Antioedematous agentsDiuretics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 27/02 - Ophthalmic agents
• A61P 27/06 - Antiglaucoma agents or miotics
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A promoting agent for the secretion of a lipid, which contains diquafosol or a salt thereof as an active ingredient, in which the type of the secretion of the lipid is of a holocrine type. An ophthalmic composition containing diquafosol or a salt thereof as an active ingredient, which is intended to be used for the promotion of the secretion of a lipid, in which the type of the secretion of the lipid is of a holocrine type. An ophthalmic composition containing diquafosol or a salt thereof, which is intended to be used in an in vivo treatment method for promoting the holocrine-type secretion of a lipid from a meibomian gland cell. An ophthalmic composition containing diquafosol or a salt thereof, which is intended to be used in an in vivo treatment method for promoting the secretion of a lipid from a meibomian gland cell, in which the lipid is at least one component selected from the group consisting of a wax ester, a triglyceride, an omega-hydroxy lipid, cholesterol, a cholesterol ester, total cholesterol, a phospholipid, a fatty acid and a fatty alcohol.

IPC Classes  ?

• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61P 27/02 - Ophthalmic agents

Abstract

The present disclosure provides an agent for treating or preventing ophthalmopathy such as presbyopia, the agent containing as an active ingredient a sulfur-containing compound having a prescribed structure.

IPC Classes  ?

• A61K 31/095 - Sulfur, selenium or tellurium compounds, e.g. thiols
• A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
• A61P 27/02 - Ophthalmic agents
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia
• C07C 323/12 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
• C07D 339/04 - Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid

Goods & Services

Educational services. Scientific and technological services; offering scientific information on diseases and on the treatment thereof; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; hosting of websites. Medical services; healthcare services; providing of medical information; medical counselling services; provision of pharmaceutical information.

Abstract

A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.

IPC Classes  ?

• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/225 - Polycarboxylic acids
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The present invention provides an aqueous composition for enhancing transferability into ocular tissue, the aqueous composition containing epinastine or a salt thereof and a quaternary ammonium compound, wherein the content ratio of the quaternary ammonium compound with respect to the epinastine or salt thereof is 0.1 part by weight or less with respect to 1 part by weight of the content of the epinastine or salt thereof.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 9/08 - Solutions
• A61K 47/16 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention pertains to an ophthalmic aqueous composition containing a silver salt, wherein a polyester resin container or a polyolefin (excluding polypropylene) resin container is filled with the ophthalmic aqueous composition. The present invention also pertains to: an ophthalmic preservative containing a silver salt, wherein a polyester resin container or a polyolefin (excluding polypropylene) resin container is filled with the ophthalmic preservative; and a method for imparting storage efficacy that meets the storage efficacy test standards of the Japan Pharmacopoeia to an ophthalmic aqueous composition, wherein the method includes a step for adding a silver salt to the ophthalmic aqueous composition, and a step for filling a polyester resin container or a polyolefin (excluding polypropylene) resin container with the ophthalmic aqueous composition. The present invention provides a preservative/system that can be widely used in ophthalmic aqueous compositions irrespective of types of active ingredients and additives.

IPC Classes  ?

• A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
• A61K 9/08 - Solutions
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 47/02 - Inorganic compounds
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention pertains to an ophthalmic aqueous composition containing a silver salt, wherein a polyester resin container or a polyolefin (excluding polypropylene) resin container is filled with the ophthalmic aqueous composition. The present invention also pertains to: an ophthalmic preservative containing a silver salt, wherein a polyester resin container or a polyolefin (excluding polypropylene) resin container is filled with the ophthalmic preservative; and a method for imparting storage efficacy that meets the storage efficacy test standards of the Japan Pharmacopoeia to an ophthalmic aqueous composition, wherein the method includes a step for adding a silver salt to the ophthalmic aqueous composition, and a step for filling a polyester resin container or a polyolefin (excluding polypropylene) resin container with the ophthalmic aqueous composition. The present invention provides a preservative/system that can be widely used in ophthalmic aqueous compositions irrespective of types of active ingredients and additives.

IPC Classes  ?

• A61K 47/02 - Inorganic compounds
• A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
• A61K 9/08 - Solutions
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention makes it possible to prepare a rebamipide-containing aqueous suspension that has similar properties to Mucosta® ophthalmic suspension UD2%, without using PVA as an additive, from an aqueous suspension that contains rebamipide or a salt thereof and at least one polymer selected from the group consisting of carmellose sodium, dextran, and polyvinylpyrrolidone.

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 9/10 - DispersionsEmulsions
• A61K 47/02 - Inorganic compounds
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 27/02 - Ophthalmic agents

Goods & Services

Pharmaceutical preparations for the treatment of cataracts, glaucoma, ocular hypertension, pinguecula, chalazion, uveitis, and eye diseases and conditions; pharmaceutical preparations, namely, collyrium, eye drops, ophthalmic preparations, and ophthalmic ointments for the treatment of eye diseases and conditions; pharmaceutical preparations for use in eye injections for the treatment of eye diseases and conditions

Abstract

−11 mol/L or less.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

The present invention provides a drug composition for treating nearsightedness, preventing nearsightedness, and/or minimizing progression of nearsightedness, including, as an active ingredient, 4-{(3S, 5ar, 6R, 7R, 8aS)-6-[(1E, 3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-butene-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoic acid, an ester thereof or a salt thereof.

IPC Classes  ?

• A61K 31/558 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions
• A61P 27/06 - Antiglaucoma agents or miotics
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

The present invention provides a pharmaceutical composition for treating myopia, preventing myopia, and/or suppressing progression of myopia, the pharmaceutical composition containing omidenepag or an ester thereof, or a salt of these, as an active ingredient.

IPC Classes  ?

• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions
• A61P 27/06 - Antiglaucoma agents or miotics
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

The purpose of the present invention is to provide an aqueous suspension composition comprising poorly water-soluble sirolimus or a salt thereof for ophthalmology, in particular, used for topical administration, such as a less invasive eye drop. The present invention is an ophthalmic aqueous suspension composition comprising sirolimus or a salt thereof and a surfactant, wherein the aqueous suspension composition has a pH of 4 to 6.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61P 27/02 - Ophthalmic agents

Abstract

The purpose of the present invention is to provide an aqueous suspension composition that contains poorly soluble sirolimus and that is for use in ophthalmology, especially in topical administration of less-invasive eye drops or the like.　This aqueous suspension composition is for use in ophthalmology, contains a surfactant and sirolimus or a salt thereof, and has a pH of 4-6.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 9/10 - DispersionsEmulsions
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to the use of valproic acid for reducing post-operative scarring following a glaucoma surgery. In one embodiment, the glaucoma surgery is glaucoma filtering surgery, which comprises creating a subconjunctival bleb. In another embodiment, the glaucoma surgery is minimally invasive glaucoma surgery (MIGS), which comprises implanting a glaucoma tube shunt under a subconjunctival space.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid

Abstract

According to some embodiments, a syringe may include a barrel; a delivery conduit; a plunger seal disposed within the barrel; and a plunger rod assembly affixed to an end of the barrel, the plunger rod assembly including a first plunger rod component comprising a first linear gear, a second plunger rod component disposed at least partially in the barrel and engaged with the plunger seal, wherein the second plunger rod component comprises a second linear gear, a first rotational gear having a plurality of gear teeth for engaging the first linear gear, and a second rotational gear having a second plurality of gear teeth for engaging the second linear gear, wherein the first rotational gear is coupled to the second rotational gear such that translation of the first plunger rod component causes translation of the second plunger rod component.

IPC Classes  ?

• A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
• A61M 35/00 - Devices for applying media, e.g. remedies, on the human body
• A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 5/31 - Syringes Details
• A61M 5/34 - Constructions for connecting the needle
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61M 39/10 - Tube connectors or tube couplings

Abstract

The present invention relates to the use of valproic acid for reducing post-operative scarring following a glaucoma surgery. In one embodiment, the glaucoma surgery is glaucoma filtering surgery, which comprises creating a subconjunctival bleb. In another embodiment, the glaucoma surgery is minimally invasive glaucoma surgery (MIGS), which comprises implanting a glaucoma tube shunt under a subconjunctival space.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 41/00 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Goods & Services

Educational services.

Goods & Services

(1) Educational services, namely, conducting virtual and in-person educational events consisting of classes, webinars, workshops and training in the field of medicine.

Goods & Services

Educational services, namely, conducting virtual and in-person educational events consisting of classes, webinars, workshops and training in the field of ophthalmology

Goods & Services

Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use; food for babies; dietary supplements for human being and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; eye drops; collyrium; ophthalmological preparations; pharmaceutical preparations for treatment of cataracts; pharmaceutical preparations for treatment of glaucoma; eye drops for treatment of glaucoma; pharmaceutical preparations for treatment of ocular hypertension; ophthalmic ointments, creams, lotions and gels; pharmaceutical preparations for use in eye injections; pharmaceutical preparations for treatment of pinguecula; pharmaceutical preparations for treatment of chalazion; pharmaceutical preparations for treatment of uveitis; eye drops for treatment of keratoconjunctival epithelial disorder; antibacterial eye drops; antiallergic eye drops; pharmaceutical agents affecting sensory organs; pharmaceutical preparations for improving focus-adjustment function declined by accommodative asthenopia; pharmaceutical preparations for treatment of accommodative asthenopia; lactose for pharmaceutical purposes; pharmaceutical preparations; reagent paper for medical purposes; diagnostic preparations for medical purposes; oiled paper for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; wrapping wafers for medicine doses; gauze for dressings; capsules for medicine; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton sticks for medical use; diapers for incontinence; diapers; diaper covers; dietary supplements for humans; nutritional supplements; dietetic beverages adapted for medical purposes; dietetic food adapted for medical purposes; beverages for babies; dietary supplements for animals; dental cements; mothproofing paper.

Abstract

The present invention pertains to diquafosol or a salt thereof, and an aqueous ophthalmic composition containing polyvinylpyrrolidone. The present invention further pertains to an aqueous ophthalmic composition for preventing or treating dry eye, the composition containing a 3% (w/v) concentration of sodium diquafosol, polyvinylpyrrolidone having a K value of 90, and silver nitrate, and the composition being characterized by being used so as to be ocularly administered at a dosage of 1 or 2 drops 2 to 4 times daily. The present invention also pertains to an aqueous ophthalmic composition for preventing or treating dry eye, the composition containing a 3% (w/v) concentration of sodium diquafosol, polyvinylpyrrolidone, and silver nitrate, the composition being characterized by being used so as to be ocularly administered at a dosage of one or two drops, two to four times daily, wherein the viscosity is 3 to 30 mPa·s at 25°C.

IPC Classes  ?

• A61P 27/04 - Artificial tearsIrrigation solutions
• A61K 9/08 - Solutions
• A61K 47/02 - Inorganic compounds
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide

Abstract

A method for changing a condition of an eyelid of a hairless animal, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A01K 67/027 - New or modified breeds of vertebrates
• A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides

Abstract

Provided is an ophthalmic composition comprising diquafosol or a salt thereof and a cationic polymer, the cationic polymer being at least one selected from the group consisting of chitosan, a chitosan derivative, a cationic (meth)acrylate copolymer, a cationic silicone polymer, a diallyl quaternary ammonium salt-acrylamide copolymer, cationic hydrolyzed keratin, cationic hydrolyzed silk, cationic hydrolyzed collagen, cationic hydrolyzed casein, cationic hydrolyzed soy protein, a cationic vinylpyrrolidone copolymer, polyvinylpyrrolidone, a dimethyldiacrylammonium chloride homopolymer, an adipic acid-dimethylaminohydroxypropyldiethylenetriamine copolymer, an adipic acid-epoxypropyldiethylenetriamine copolymer and an acrylamide-β-methacryloyloxyethyltrimethylammoniummethyl sulfate copolymer.

IPC Classes  ?

• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 27/04 - Artificial tearsIrrigation solutions

Abstract

An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.

IPC Classes  ?

• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61K 9/08 - Solutions
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61P 27/02 - Ophthalmic agents
• A61P 31/04 - Antibacterial agents
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/02 - Inorganic compounds
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• C07J 5/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, and substituted in position 21 by only one singly bound oxygen atom
• C07C 31/18 - Polyhydroxylic acyclic alcohols
• C08G 65/00 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule

Abstract

The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.

IPC Classes  ?

• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The purpose of the present invention is to suppress the reduction of the percentage of the iodine content in an ophthalmic composition during storage. This ophthalmic product (A) according to the present invention is made by accommodating, in a container (10), an iodine raw liquid (I) containing iodine and poly vinyl alcohol as active ingredients, and the container (10) is made of at least one material selected from the group consisting of a fluorine-based resin, a polyethylene-based resin, and a polyethylene terephthalate resin.

IPC Classes  ?

• A61P 27/02 - Ophthalmic agents
• A61P 27/04 - Artificial tearsIrrigation solutions
• A61P 31/04 - Antibacterial agents
• A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
• B65D 41/04 - Threaded or like caps or cap-like covers secured by rotation
• A61K 33/18 - IodineCompounds thereof
• A61K 31/765 - Polymers containing oxygen